Stock comparison
Halozyme Therapeutics
Novartis AG
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
NVS
Novartis AG
Market cap
$290.64B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | NVS | Winner |
|---|---|---|---|
| Warren Buffett | 79B | 62C | HALO |
| Benjamin Graham | 83A | 69B | HALO |
| Philip Fisher | 65B | 53C | HALO |
| Peter Lynch | 53D | 35D | HALO |
| Joel Greenblatt | 40D | 46D | NVS |
| Charlie Munger | 80C | 69C | HALO |
| Terry Smith | 84A | 66B | HALO |
Side-by-side metrics
| Metric | HALO | NVS |
|---|---|---|
| Market cap | $8.1B | $290.64B |
| P/E (TTM) | 24.0x | 21.3x |
| EV/EBIT | 10.2x | 19.2x |
| ROIC (TTM) | 23.65% | 14.89% |
| Gross margin | 81.24% | 75.13% |
| Net margin | 23.13% | 24.31% |
| Revenue CAGR 5y | 33.23% | 5.66% |
| EPS CAGR 5y | -1.98% | -9.29% |
| Debt / Equity | 1.0x | 1.2x |
| Dividend yield | 0.0% | 3.12% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- Revenue CAGR 5y33.23%vs 5.66%+83%
- EPS CAGR 5y-1.98%vs -9.29%+79%
- EV/EBIT10.2xvs 19.2x+47%
- ROIC (TTM)23.65%vs 14.89%+37%
NVS leads on
- Dividend yield3.12%vs 0.0%+100%
- Market cap$290.64Bvs $8.1B+97%
- P/E (TTM)21.3xvs 24.0x+11%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.